Form 4: Tonix Pharmaceuticals Director Margaret Smith Bell Acquires Stock Options

Director Margaret Smith Bell acquired 10,000 stock options in Tonix Pharmaceuticals Holding Corp. on May 13, 2025, according to a Form 4 filing.

Summary

• On May 13, 2025, Margaret Smith Bell, a director of Tonix Pharmaceuticals Holding Corp., acquired 10,000 stock options at an exercise price of $20.18.
• These options were granted under the company's Amended and Restated 2020 Stock Incentive Plan.
• The options vest on the earlier of the one-year anniversary of the grant date (May 13, 2026) or the Issuer's 2026 Annual Meeting of Stockholders and expire on May 13, 2035.
• Following the transaction, Ms. Bell directly owns 10,000 shares of Tonix Pharmaceuticals Holding Corp.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which is neither overtly positive nor negative.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the granting of stock options suggests an incentive for the director to contribute to the company's long-term success.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates activity related to director compensation and equity ownership.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates

Keywords

Form 4, Tonix Pharmaceuticals, Stock Options, Director, Beneficial Ownership, TNXP, Margaret Smith Bell